Sustained release drug delivery to the lungs. An option for the future

Clinical Pharmacokinetics

Volumn 39, Issue 1, 2000, Pages 1-4

  Hardy, John G ^a   Chadwick, Terence S ^a  

^a Quadrant Healthcare PLC   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPID;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; LUNG; LUNG ALVEOLUS; PARTICLE SIZE; PARTICULATE MATTER; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SUSTAINED DRUG RELEASE;

EID: 0033925098     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200039010-00001     Document Type: Review

References (29)

1. 1. Smith PL. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J Control Release 1997; 46: 99-106
2. 2. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabetic Med 1997; 14: 63-72
3. 3. Patton JS, Bukar J, Nagrajan S. Inhaled insulin. Adv Drug Deliv Rev 1999; 35: 235-47
4. 4. Barnes PJ. Asthma therapy with aerosols: clinical relevance for the next decade. J Aerosol Med 1996; 9: 131-41
5. 5. Ben-Jebria A, Chen D, Eskew ML, et al. Large porous particles for sustained protection from carbachol-induced bronchocon-striction in guinea pigs. Pharm Res 1999; 16: 555-61
6. 6. Barnes PJ, Adcock IM. Transcription factors and asthma. Eur Respir J 1998; 12:221-34
7. 7. Pavia D, Thomson ML, Clarke SW, et al. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 1977; 32: 194-7
8. 8. Kreyling WG, Blanchard JD, Godleski JJ, et al. Anatomic localization of 24- and 96-h particle retention in canine airways. J Appl Physiol 1999; 87: 269-84
9. 9. Brain JD. Macrophages in the respiratory tract. In: Fishman AP, Fisher AB, editors. Handbook of physiology: the respiratory system 1. Bethesda (MD): American Physiological Society, 1985: 447-71
10. 10. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Del Rev 1996; 19: 3-36
11. 11. Bowden DH. Macrophages, dust, and pulmonary diseases. Expl Lung Res 1987; 12: 89-107
12. 12. Newman SP, Agnew JE, Pavia D, et al. Inhaled aerosols: lung deposition and clinical applications. Clin Phys Physiol Meas 1982; 3: 1-20
13. 13. Edwards DA, Ben-Jebria A, Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998 Aug; 85 (2): 379-85
14. 14. Vanbever R, Mintzes JD, Wang J, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res 1999; 16: 1735-42
15. 15. Nicholas TE. Pulmonary surfactant: no mere paint on the alveolar wall. Respirology 1996; 1: 247-57
16. 16. Evora C, Soriano I, Rogers RA, et al. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J Control Release 1998; 51: 143-52
17. 17. Hardy JG. Drug delivery to the respiratory tract. In:Perkins AC, Frier M, editors. Nuclear medicine in pharmaceutical research. London: Taylor & Francis, 1999: 41-56
18. 18. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999; 12 Suppl. 1: S9-17
19. 19. Costantino HR, Carrasquillo KG, Cordero RA, et al. Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 1998; 87: 1412-20
20. 20. Taylor LS, Williams AC, York P. Particle size dependent molecular rearrangements during the dehydration of trehalose dihydrate: in situ FT-Raman spectroscopy. Pharm Res 1998; 15: 1207-14
21. 21. Taylor LS, Zografi G. Sugar-polymer hydrogen bond interactions in lyophilized amorphous mixtures. J Pharm Sci 1998; 87: 1615-21
22. 22. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsulation 1998; 15: 699-713
23. 23. Talton J, Fitz-Gerald J, Singh R, et al. Nano-thin coastings for improved lung targeting of glucocorticoid dry powders: in vitro and in vivo characteristics. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Proceedings of Respiratory Drug Delivery VII; 2000 May 14-18; Tarpon Springs (FL). Raleigh (NC): Serentec Press, 2000; 1: 67-74
24. 24. Suarez S, Gonzalez-Rothi RJ, Schreier H, et al. Effect of dose and release rate on pulmonary targeting of liposomal triamcinolone acetonide phosphate. Pharm Res 1998; 15: 461-5
25. 25. Mobley WC. The effect of jet-milling on lyophilized liposomes. Pharm Res 1998; 15: 149-52
26. 26. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-71
27. 27. Wang J, Ben-Jebria A, Edwards DA. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 1999; 12: 27-36
28. 28. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000; 17: 168-74
29. 29. Wolff RK, Allen DL, Hughes BL, et al. The case for route-dependent toxicology comparisons: using large animal models to speed clinical development of inhaled proteins. In: Dalby RN, Byron PR, Farr SJ, et al., editors. Proceedings of Respiratory Drug Delivery VII; 2000 May 14-18; Tarpon Springs (FL). Raleigh (NC): Serentec Press, 2000; 1: 163-70